The Genomic Landscape of Childhood and Adolescent Melanoma
暂无分享,去创建一个
Li Ding | Jinghui Zhang | Matthew Parker | Susana Raimondi | Heather L. Mulder | Michael Edmonson | Elaine R Mardis | Michael Rusch | Matthew A. Wyczalkowski | Erin K. Hedlund | Michael Dyer | John Easton | Stanley Pounds | Matthew A Wyczalkowski | Yongjin Li | Sheila Shurtleff | Panduka Nagahawatte | David W Ellison | Gang Wu | Michael C. Rusch | Michael N. Edmonson | Erin Hedlund | Armita Bahrami | R. Wilson | E. Mardis | J. Downing | S. Shurtleff | S. Raimondi | W. Evans | L. Ding | M. Edmonson | Charles Lu | D. Ellison | J. Easton | Gang Wu | A. Bahrami | A. Pappo | M. Rusch | Panduka Nagahawatte | H. Mulder | Jinghui Zhang | M. Dyer | S. Pounds | Yongjin Li | R. Tatevossian | J. Dalton | Richard K Wilson | Charles Lu | James R Downing | William E Evans | Alberto Pappo | Heather Mulder | M. Valentine | F. Navid | Seungjae Lee | Zhifa Liu | Marcus Valentine | Fariba Navid | Ruth G Tatevossian | James Dalton | James Davenport | Zhirong Yin | Vadodaria Bhavin | Yergeau Donald | Z. Yin | James R. Davenport | Seungjae Lee | Zhifa Liu | Matthew Parker | V. Bhavin | Yergeau Donald | Zhirong Yin | R. Wilson | Marcus L Valentine
[1] S. Davis,et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.
[2] P. Leboit. Pathology and genetics of skin tumours , 2006 .
[3] D. Pinkel,et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.
[4] S. Egyházi,et al. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. , 2010, The Journal of investigative dermatology.
[5] A. Sarasin,et al. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. , 2005, Mutation research.
[6] C. Milagre,et al. Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression , 2011, Pigment cell & melanoma research.
[7] D. Pinkel,et al. MC1R germline variants confer risk for BRAF-mutant melanoma. , 2006, Science.
[8] A. Hauschild,et al. Melanoma risk in congenital melanocytic naevi: a systematic review , 2006, The British journal of dermatology.
[9] W. McWhirter,et al. Risk factors for childhood melanoma in Queensland, Australia , 1997, International journal of cancer.
[10] Li Ding,et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.
[11] B. Bett. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. , 2005, Journal of the American Academy of Dermatology.
[12] A. Marghoob,et al. Large Congenital Melanocytic Nevi and the Risk for Development of Malignant Melanoma and Neurocutaneous Melanocytosis , 2000, Pediatrics.
[13] R. Wood,et al. DNA polymerases and cancer , 2011, Nature Reviews Cancer.
[14] M. Mihm,et al. Childhood melanoma: a clinicopathological study of 22 cases , 1997, Melanoma research.
[15] K. Gow,et al. Melanoma in children and adolescents. , 2007, Surgical oncology.
[16] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[17] Jenine K. Harris,et al. Incidence of Childhood and Adolescent Melanoma in the United States: 1973–2009 , 2013, Pediatrics.
[18] T. Flotte,et al. Cutaneous melanoma and atypical spitz tumors in childhood , 1995, Cancer.
[19] S. Swetter,et al. Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults—The Stanford Experience 1995–2008 , 2010, Pediatric dermatology.
[20] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[21] F. Haluska,et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.
[22] V. Prieto,et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool , 2009, Journal of cutaneous pathology.
[23] D. Lazovich,et al. Germline melanoma susceptibility and prognostic genes: a review of the literature. , 2012, Journal of the American Academy of Dermatology.
[24] Li Ding,et al. C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. , 2014 .
[25] P. Hanawalt,et al. Transcription-coupled DNA repair: two decades of progress and surprises , 2008, Nature Reviews Molecular Cell Biology.
[26] Matthew W. Wilson,et al. A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.
[27] F. Sera,et al. MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.
[28] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[29] T. Fennell,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[30] S. Purcell. Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults—The Stanford Experience 1995–2008 , 2011 .
[31] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .
[32] D. Schadendorf,et al. Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.
[33] N. Sebire,et al. Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS , 2013, The Journal of investigative dermatology.
[34] T. Fears,et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Iwei Yeh,et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.
[36] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[37] Daniel Pinkel,et al. Classifying melanocytic tumors based on DNA copy number changes. , 2003, The American journal of pathology.
[38] R. Marais,et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.
[39] J. Bartek,et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.
[40] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[41] G. Pfeifer,et al. Mutations induced by ultraviolet light. , 2005, Mutation research.
[42] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[43] D. Elder,et al. Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children , 2013, The American journal of surgical pathology.
[44] Li Ding,et al. C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.
[45] Iwei Yeh,et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.
[46] D. Pinkel,et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.
[47] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[48] Claus Garbe,et al. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. , 2008, Advances in experimental medicine and biology.